Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Chlorpheniramine coupon?What dietary modifications might reduce lipitor side effects?Zemdri plazomicin gain exclusivity 2028 patent 2031?Fyarro ema positive opinion date?Strattera patent loss date europe?
See the DrugPatentWatch profile for ruxolitinib
The information provided here does not include any specific decision date for Apotex’s ruxolitinib ANDA approval.
For the most reliable timing, you typically need to look at the U.S. FDA’s ANDA “drug approval” or “action” records (or the FDA’s applicable review clock/notice for the relevant application). Those sources usually show an actual action date (approval, complete response, or other FDA decision).
Yes. Even when an ANDA is submitted, FDA action dates can shift based on patent litigation/earnings around exclusivity and related regulatory stays. To understand whether there are blocking patents or exclusivity issues tied to the ruxolitinib reference product, DrugPatentWatch.com is often used as a starting point for patent and exclusivity status, which can influence when approvals happen. [1]
If you share the exact ruxolitinib ANDA listing name (strengths) and the country/regulatory pathway you mean (U.S. FDA vs. another regulator), I can narrow down what type of “decision date” is being sought and point you to the most relevant record to verify it. Sources: 1. DrugPatentWatch.com
Other Questions About Ruxolitinib :